Deep Phenotyping of Bone Disease in Type 2 Diabetes and Relations to Diabetic Neuropathy

Objectives:The goal of this cross sectional clinical trial is to examine the phenotype of bone disease in type 2 diabetes.The main aims are to:Compare bone microarchitecture, bone biomechanical competence, and bone turnover markers as well as postural control in T2D patients with and without fractures.Examine how autonomic and peripheral neuropathy affects bone microarchitecture, bone material strength and bone turnover markers as well as postural control in T2D.Methods:The trial is of cross-sectional design and consists of examinations includingBlood samples to analyze bone markers, glycemic state i.e.Bone scans including dual energy x-ray absorptiometry (DXA) and high resolution peripheral quantitative computed tomography (HRpQCT) to evaluate Bone Mineral Density, t-score and bone structure.Microindentation to evaluate bone material strengthSkin autofluorescence to measure levels of advanced glycation endproducts (AGEs) in the skinAssesment of nerve function (peripheral and autonomic)Assesment of postural control, muscle strength and gaitParticipants:A total of 300 type 2 diabetes patients divided to three groups:160 with no history of fractures or diabetic neuropathy100 with a history of fracture(s)40 with autonomic neuropathy or severe peripheral neuropathy

Inclusion Criteria:Men and women with minimum 40 years of age.Diagnosis of T2D. At least one of the following criteria must be met at diagnosis:HbA1c ≥ 48 mmol/mol (6,5 %)Plasma glucose ≥ 11,1 mmol/lFasting plasma glucose ≥7,0 mmol/l Clinical effect of oral antidiabetic medication strengthens the diagnosis.Diagnosis of diabetes at least one year prior to inclusion of the study to avoid honeymoon diabetes.A history of fracture(s) (confirmed by radiographs analyzed by radiologist) following the diabetes diagnosis (T2D F+ group)Diagnosed with severe peripheral (VPT ≥ 50) or autonomic neuropathy defined by cardiac autonomic reflex tests or severe abnormalities in orthostatic blood pressure (T2D N+ group)Signed the informed consent.Not defined by the exclusion criteria.Exclusion Criteria:Severe decreased liver function (Alanin amino-transaminase (ALAT) >250 U/l, Gamma-Glutamyltransferase (GGT) >150 U/l).Moderate to severe kidney dysfunction, estimated Glomerular Filtration Rate (eGFR) <15 mmol/L/1,73m2.Pregnancy or breast feeding.Active malignancy or terminal ill.Previous chemotherapy or immunomodulating treatmentKnown severe vitamin deficiencyCurrent or previous alcohol- or drug abuse.Not being able to understand Danish written and/or verbally.Terms according to investigators judgement that makes subjects unsuitable to participate including lack of ability to understand and comply with instructions and/or reduced physical ability, limiting the ability to participate in the examinations.Participating in other clinical studies utilizing experimental treatment or medication.Subjects with pathologic fractures (defined as fractures due to local tumors, tumor-like lesions, or focal demineralization as visualized on radiographs).Primary hyperparathyroidism, Paget's disease and other metabolic bone diseases, uncontrolled thyrotoxicosis, celiac disease not controlled by diet, known hypogonadism, severe COPD, hypopituitarism, Cushing's disease.Fracture < 6 month agoInitiation of antiresorptive or bone anabolic drugs <12 months ago to ensure stable bone turnover markers.History of fractures following the diagnosis of diabetes (T2D F-/N- and T2D N+ groups).History of peripheral or autonomic neuropathy defined by cardiac autonomic reflex tests or severe abnormalities in orthostatic blood pressure (T2D F-/N- group).